Asthma: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• NLRP3 0
• IL-4 0
• MAPK 0
• PI3K 0
• TSLP 2
• STAT3 0
• AKT 0
• IL-13 0
• mTOR 0
• NRF2 0
• TNF 0
• TLR4 0
• GLP-1 0
• IL-17 0
• JAK 1
• PPAR 0
• HIF-1 0
• IL-6 0
• JNK 0
• AMPK 0
• ERK 0
• CD40 0
• COX-2 0
• HMGB1 0
• IL-1 1
• MMP-9 0
• STING 0
• EGFR 0
• SIRT1 0
• TP53 0
• YAP 0
• CTNNB1 0
• GPX4 0
• METTL3 0
• PD-1 0
• PDE4 0
• PTEN 0
• VEGF 0
• CCR5 0
• CFTR 0
• PD-L1 0
• PKM2 0
• ALK 1
• BDNF 0
• CD19 0
• CD38 0
• CXCR4 0
• FGFR 0
• FTO 0
• GIP 0
• HDAC 0
• IGF1R 0
• IL-23 0
• KIT 0
• MYC 0
• PCSK9 0
• SGLT2 0
• STK11 0
• ACE2 0
• APOE 0

24 of 3,813 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Targeting airway lymphocytes in asthma and biologics treatment (TARGET-AIR-LAB)

  Karolinska Institutet· Stockholm, Sweden· EU contribution €1,999,008· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-CSA

  Socio-environmental nexus for sustainable health outcomes in pediatric asthma: a twinning initiative (SENSO-TWIN)

  Panepistimio Patron· Rio Patras, Greece· EU contribution €1,499,870· until Dec 2029· 5 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  A doctoral training programme for next-generation LUNG-targeted non-viral GENEtic MEDicines (LUNG-GENEMED)

  Politecnico di Milano· Milano, Italy· EU contribution €3,876,613· until Nov 2030· 7 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Revealing the neuroimmune communication for better treatment outcomes in food allergy (AllergyREBELL)

  Karolinska Institutet· Stockholm, Sweden· EU contribution €252,180· until Oct 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Semiquantification based on ionization efficiency for human exposure leveraging ion mobility separation (semiQ2)

  Agencia Estatal Consejo Superior de Investigaciones Cientificas· Madrid, Spain· EU contribution €209,915· until Sept 2028

  The disease is named only in the funder's project summary, not in the title.

5 of 25 running projects, newest first. Listed amounts together: €58.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Probiotics and Insulin Resistance in Obese Asthmatics

  NCT05949255· University of Alabama at Birmingham· Updated 5 Nov 2026

  “Lost coordinator and statistician before no cost extension study could be completed.”Registry text, quoted unchanged. Source

• Withdrawn

  Study of Formoterol 6 mcg/Fluticasone 125 mcg by Eurofarma Laboratórios S.A. Versus Alenia® 6 mcg/200 mcg in Patients With Asthma (FORASMA)

  NCT07318350· Eurofarma Laboratorios S.A.· Updated 23 Oct 2026

  “Strategic change in development priorities.”Registry text, quoted unchanged. Source

• Terminated

  Safety and Feasibility Study of Intranasal Mesenchymal Trophic Factor (MTF) for Treatment of Asthma

  NCT02192736· Translational Biosciences· Updated 1 Oct 2026

  “Did not meet recruitment goals”Registry text, quoted unchanged. Source

• Withdrawn

  Combination of High-flow Nasal Oxygen (Optiflow) and Vibrating Membrane Nebuliser (Aerogen) in the Pre-hospital Setting - Before/After Study

  NCT07791992· Centre Hospitalier Sud Francilien· Updated 28 Aug 2026

  “Le projet n'a pas obtenu l'autorisation réglementaire.”Registry text, quoted unchanged. Source

• Terminated

  Self-Management Of Asthma By Forced Oscillation Technique

  NCT04963140· Restech Srl· Updated 26 Aug 2026

  “The study was terminated early due to an unexpected difficulty at the study sites in recruiting patients who met all the inclusion criteria.”Registry text, quoted unchanged. Source

• Suspended

  To Identify Persons Who Are Susceptible to WSP-induced Inflammation and Examine the Role of GSTM1 and Other Factors in This Susceptibility

  NCT02767973· University of North Carolina, Chapel Hill· Updated 20 Aug 2026

  “We no longer have access to the Wood smoke chamber and will need to rework how we do the wood smoke exposures.”Registry text, quoted unchanged. Source

• Suspended

  Characterization of Adult Subjects for Asthmatic Research Studies

  NCT01508078· University of California, San Francisco· Updated 14 Aug 2026

  “The restrictions on research imposed for the COVID-19 pandemic prevented us from continuing recruitment and visits. At this stage our funding is not sufficient to continue enrollment so we will put the study in a hold pattern.”Registry text, quoted unchanged. Source

• Withdrawn

  Coping With Asthma Throughout Life Management Program

  NCT07044388· Duke University· Updated 7 Aug 2026

  “PI departure from institution”Registry text, quoted unchanged. Source

• Withdrawn

  A Phase 1 Study of Cizutamig in IgE Mediated Diseases

  NCT07408869· Candid Therapeutics· Updated 22 Jul 2026

  “Sponsor decision”Registry text, quoted unchanged. Source

• Terminated

  Developing a Childhood Asthma Risk Passive Digital Marker

  NCT05826561· Indiana University· Updated 21 Jul 2026

  “NIH funding was terminated due to new agency priorities.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Changes in Symptom and Quality of Life in Patients With Uncontrolled Asthma Treated With Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI)

  NCT07933510· AstraZeneca· Source

• Real-world Study Assessing Efficacy of TezepeLumaB in Patients With Severe Asthma Regardless of Phenotype in Russia

  NCT06566885· AstraZeneca· Source

• A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-2)

  NCT07782996· GlaxoSmithKline· Source

• Sustainable Inhaler Prescribing in Intermediate Care Units

  NCT07933913· Consorci Sanitari de l'Alt Penedès i Garraf· Source

• A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.

  NCT05776927· Novartis Pharmaceuticals· Source

• A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma

  NCT06023589· AstraZeneca· Source

• REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study

  NCT06041386· GlaxoSmithKline· Source

• Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma

  NCT05222529· Novartis Pharmaceuticals· Source

• Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment

  NCT07444567· AstraZeneca· Source

• Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma

  NCT06307665· AstraZeneca· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 18
• Organoids 2
• Mendelian Randomization Analysis 79
• Gene Expression Profiling 73
• Sequence Analysis, RNA 7
• Whole Genome Sequencing 1
• Exome Sequencing 2
• Proteomics 26
• Metabolomics 47
• Mass Spectrometry 16
• Flow Cytometry 18
• Immunohistochemistry 12
• Liquid Biopsy 1
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 12
• Machine Learning 67
• Deep Learning 10
• Cohort Studies 249
• Genome-Wide Association Study 99

• Alantolactone inhibits T-cell lymphoma progression by suppressing CD47 expression via the PI3K/AKT and ERK signaling pathways.

  Apoptosis, Aug 2026

See which targets of this disease your abstract mentions, and go to the people working on them.